keyword
MENU ▼
Read by QxMD icon Read
search

rituximab and lymphoma relapse

keyword
https://www.readbyqxmd.com/read/28640132/treatment-outcome-of-diffuse-large-b-cell-lymphoma-involving-the-head-and-neck-two-institutional-study-for-the-significance-of-radiotherapy-after-r-chop-chemotherapy
#1
Yoo-Kang Kwak, Byung-Ock Choi, Sung Hwan Kim, Joo Hwan Lee, Dae Gyu Kang, Jong Hoon Lee
This study was performed to analyze the treatment outcome for diffuse large B-cell lymphoma (DLBCL) involving the head and neck and to evaluate the role of radiotherapy in the rituximab era. Fifty-six patients diagnosed with DLBCL involving the head and neck were assessed. All patients were treated with 6 cycles of rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone (R-CHOP). After chemotherapy, radiation was delivered to the head and neck area in a median dose of 36 Gy. Radiation was delivered using 3-dimensional radiotherapy (n  =  25) or intensity-modulated radiotherapy (n  =  31)...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28633365/phase-ii-study-of-copanlisib-a-pi3k-inhibitor-in-relapsed-or-refractory-indolent-or-aggressive-lymphoma
#2
M Dreyling, F Morschhauser, K Bouabdallah, D Bron, D Cunningham, S E Assouline, G Verhoef, K Linton, C Thieblemont, U Vitolo, F Hiemeyer, M Giurescu, J Garcia-Vargas, I Gorbatchevsky, L Liu, K Koechert, C Peña, M Neves, B H Childs, P L Zinzani
Background: Copanlisib is a pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor with predominant activity against the α- and δ- isoforms. Patients and methods: This phase II study evaluated the response rate of copanlisib administered intravenously on days 1, 8, and 15 of a 28-day cycle, in patients with indolent or aggressive malignant lymphoma. Archival tumor tissues were used for immunohistochemistry, gene-expression profiling, and mutation analysis...
June 14, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
https://www.readbyqxmd.com/read/28633037/treatment-with-methotrexate-rituximab-and-cytosine-arabinoside-followed-by-autologous-stem-cell-transplantation-in-primary-central-nervous-system-lymphoma-a-single-center-experience
#3
Pinar Ataca Atilla, Erden Atilla, Sinem Civriz Bozdag, Meltem Kurt Yuksel, Selami Kocak Toprak, Pervin Topcuoglu, Taner Demirer, Osman Ilhan, Onder Arslan, Gunhan Gurman, Muhit Ozcan
OBJECTIVE/BACKGROUND: Primary central nervous system lymphoma (PCNSL) is associated with worst prognosis compared with other aggressive non-Hodgkin's lymphomas. However, recent trials have demonstrated that long-term progression-free survival can be achieved by immunochemotherapy. Our goal is to present our experience in aggressive PCNSL in this study. METHODS: We retrospectively evaluated the clinical features and management of 13 PCNSL patients who were diagnosed and treated between 2006 and 2015...
June 15, 2017: Hematology/oncology and Stem Cell Therapy
https://www.readbyqxmd.com/read/28628883/pros-and-cons-of-rituximab-maintenance-in-follicular-lymphoma
#4
REVIEW
Lu Zhang, Michele Ghielmini, Bruce D Cheson, Chaitra Ujjani
Follicular lymphoma (FL) is the most prevalent indolent non-Hodgkin lymphoma. Most patients present with advanced disease and are incurable with current therapy. The approval of rituximab has revolutionized the treatment of follicular lymphoma when administered in the induction setting for high-tumor burden disease, but the use of rituximab as a maintenance therapy (MR) continues to be a point of controversy. In this article, we review the main data and arguments in favor and against MR in FL. In summary, most studies have demonstrated a significant benefit in progression-free or event-free survival in this notoriously recurrent disease; however, long-term outcomes could not consistently demonstrate to be improved with this intervention...
June 16, 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/28614905/long-term-follow-up-of-chemoimmunotherapy-with-rituximab-oxaliplatin-cytosine-arabinoside-dexamethasone-road-in-patients-with-relapsed-cd20-b-cell-non-hodgkin-lymphoma-results-of-a-study-of-the-mayo-clinic-cancer-research-consortium-mccrc-mc0485-now-known-as
#5
Thomas E Witzig, Patrick B Johnston, Betsy R LaPlant, Paul J Kurtin, Levi D Pederson, Dennis F Moore, Nassim H Nabbout, Daniel A Nikcevich, Kendrith M Rowland, Axel Grothey
Patients with relapsed aggressive non-Hodgkin lymphoma (NHL) are often treated with platinum-based chemoimmunotherapy regimens in preparation for autologous stem cell transplant. We sought to reduce toxicity and maintain efficacy by using oxaliplatin with rituximab, cytarabine and dexamethasone (ROAD) in a phase II clinical trial in patients who had relapsed after one prior regimen. ROAD was delivered q21 days and consisted of rituximab 375 mg/m2 IV weekly x 4 doses (cycle 1 only); dexamethasone 40 mg PO/IV d2 - 5; oxaliplatin 130 mg/m2 IV d2; cytarabine 2000 mg/m2 IV x two doses on days 2 - 3; and pegfilgrastim 6 mg SC on d4...
June 14, 2017: American Journal of Hematology
https://www.readbyqxmd.com/read/28612278/efficacy-of-prophylactic-irradiation-to-the-contralateral-testis-for-patients-with-advanced-stage-primary-testicular-lymphoma-an-analysis-of-outcomes-at-a-single-institution
#6
Ryouji Tokiya, Eisaku Yoden, Kei Konishi, Nobuhiko Kamitani, Junichi Hiratsuka, Risa Koresawa, Tadashi Hirose, Fuminori Sano, Hirotoshi Tokunaga, Toshinori Kondo, Hideho Wada, Takashi Sugihara
BACKGROUND: Primary testicular lymphoma (PTL) is a rare, extranodal lymphoma that often relapses in the contralateral testis. We evaluated outcomes in patients with any stage of PTL who had received CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisolone) with rituximab chemotherapy and prophylactic radiotherapy to the contralateral testis. METHODS: We retrospectively identified 15 patients (median age 66 years; range 39-81) diagnosed with diffuse large B-cell PTL in the period 2000-2014...
June 13, 2017: International Journal of Hematology
https://www.readbyqxmd.com/read/28606176/rituximab-containing-reduced-intensity-conditioning-improves-progression-free-survival-following-allogeneic-transplantation-in-b-cell-non-hodgkin-lymphoma
#7
Narendranath Epperla, Kwang Woo Ahn, Sairah Ahmed, Madan Jagasia, Alyssa DiGilio, Steven M Devine, Samantha Jaglowski, Vanessa Kennedy, Andrew R Rezvani, Sonali M Smith, Anna Sureda, Timothy S Fenske, Mohamed A Kharfan-Dabaja, Phillipe Armand, Mehdi Hamadani
BACKGROUND: In B cell non-Hodgkin lymphoma (B-NHL), rituximab-containing reduced-intensity conditioning regimens (R-RIC) have been shown to provide favorable outcomes in single-arm studies; however, large multicenter studies comparing R-RIC and non-rituximab-containing reduced-intensity conditioning regimens (nonR-RIC) have not been performed. Using the CIBMTR database, we report the outcomes of R-RIC versus nonR-RIC regimens in B-NHL. METHODS: We evaluated 1401 adult B-NHL patients undergoing allogeneic hematopoietic cell transplantation (allo-HCT) who received nonR-RIC (n = 1022) or R-RIC (n = 379) regimens...
June 12, 2017: Journal of Hematology & Oncology
https://www.readbyqxmd.com/read/28593485/diffuse-large-b-cell-lymphoma-presenting-as-bilateral-renal-infiltration-leading-to-acute-kidney-injury
#8
Tomoe Okubo, Shuma Hirashio, Minako Shimizu, Yoshiaki Kuroda, Shigehiro Doi, Takao Masaki
Acute kidney injury (AKI) because of bilateral renal infiltration is an uncommon presentation of diffuse large B-cell lymphoma (DLBCL). A 52-year-old man presented to our institution with AKI and complaints of fatigue. Ultrasonography revealed a large, 15 cm granulomatous mass arising from the bilateral kidneys. The mass was biopsied laparoscopically, and histopathological analysis revealed evidence of DLBCL. The patient subsequently underwent R-CHOP therapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone)...
June 7, 2017: CEN Case Reports
https://www.readbyqxmd.com/read/28592170/current-options-to-manage-waldenstr%C3%A3-m-s-macroglobulinemia
#9
Giulia Benevolo, Maura Nicolosi, Elisa Santambrogio, Umberto Vitolo
Waldenström's macroglobulinemia (WM) is a rare, incurable B-cell lymphoma, with a median survival of 5-10 years in symptomatic patients. There is no consensus on the standard of care and several agents are currently used in these patients. Areas covered: In this article, we will review the use of standard therapies and new drugs investigated such as monoclonal antibodies, proteasome inhibitors, immunomodulatory agents, Bruton's tyrosine kinase inhibitors and novel agents in early-stage development. Expert commentary: RCD (Rituximab/Cyclophosphamide/Dexamethasone) is an effective and safe treatment in first line in WM...
June 19, 2017: Expert Review of Hematology
https://www.readbyqxmd.com/read/28581466/high-dose-chemotherapy-and-autologous-stem-cell-transplantation-for-primary-central-nervous-system-lymphoma-a-multi-centre-retrospective-analysis-from-the-united-kingdom
#10
S Kassam, E Chernucha, A O'Neill, C Hemmaway, T Cummins, S Montoto, A Lennard, G Adams, K Linton, P McKay, D Davies, C Rowntree, S Easdale, T A Eyre, R Marcus, K Cwynarski, C P Fox
The prognosis of patients with primary central nervous system lymphoma (PCNSL) has improved in recent years. This has partly been achieved by remission induction protocols incorporating high-dose methotrexate (HD-MTX) and rituximab. Given the high rates of relapse, consolidation therapy is usually considered in first response. Whole brain radiotherapy may prolong PFS but appears to confer no long-term survival advantage and is associated with significant neurocognitive dysfunction. Attempts to improve efficacy and reduce neurotoxicity of consolidation therapy have included thiotepa-based high-dose chemotherapy and autologous stem cell transplant (HDC-ASCT)...
June 5, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28559537/high-dose-chemotherapy-with-autologous-haematopoietic-stem-cell-support-for-relapsed-or-refractory-primary-cns-lymphoma-a-prospective-multicentre-trial-by-the-german-cooperative-pcnsl-study-group
#11
B Kasenda, G Ihorst, R Schroers, A Korfel, I Schmidt-Wolf, G Egerer, L von Baumgarten, A Röth, J Bloehdorn, R Möhle, M Binder, U Keller, M Lamprecht, M Pfreundschuh, E Valk, H Fricker, E Schorb, K Fritsch, J Finke, G Illerhaus
To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary CNS lymphoma (PCNSL). We conducted a single-arm multicentre study for immunocompetent patients (<66 years) with PCNSL failing high-dose methotrexate (HD-MTX) based chemotherapy. Induction consisted of 2 courses of rituximab (375 mg/m(2)), high-dose cytarabine (2 × 3 g/m(2)) and thiotepa (40 mg/m(2)) with collection of stem cells in between. Conditioning for HCT-ASCT consisted of rituximab 375 mg/m(2), carmustine 400 mg/m(2) and thiotepa (4 × 5 mg/kg)...
May 31, 2017: Leukemia: Official Journal of the Leukemia Society of America, Leukemia Research Fund, U.K
https://www.readbyqxmd.com/read/28543967/central-nervous-system-involvement-of-primary-cutaneous-diffuse-large-b-cell-lymphoma-leg-type-13-cases
#12
LETTER
E Gardette, A Maraval, F Brunet-Possenti, G Quereux, H Beltraminelli, I Templier, J Hodel, E Scherman, E Durot, M Bagot, A Pham-Ledard, F Grange, M Beylot-Barry, S Ingen-Housz-Oro
No abstract text is available yet for this article.
May 23, 2017: Journal of the European Academy of Dermatology and Venereology: JEADV
https://www.readbyqxmd.com/read/28539536/remission-induction-therapy-with-rituximab-for-microscopic-polyangiitis-a-feasibility-study
#13
Ayako Saito, Yoichi Takeuchi, Saeko Kagaya, Yoshie Ojima, Hirotaka Fukami, Hiroyuki Sato, Ken Matsuda, Tasuku Nagasawa
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is systemic vascular inflammation. Microscopic polyangiitis (MPA) is a major type of AAV in Japan. MPA often affects the kidneys and lungs, leading to death if untreated. Induction therapy (i.e., initial treatment) for MPA has not been optimized, although methylprednisolone and cyclophosphamide are commonly used. Recently, rituximab (RTX) (a monoclonal antibody against the protein CD20) has also been used to treat refractory AAV. RTX at 375 mg/m(2)/week for 4 weeks (i...
2017: Tohoku Journal of Experimental Medicine
https://www.readbyqxmd.com/read/28533060/autologous-stem-cell-transplantation-for-follicular-lymphoma-favorable-long-term-survival-irrespective-of-pretransplantation-rituximab-exposure
#14
Ana Jiménez-Ubieto, Carlos Grande, Dolores Caballero, Lucrecia Yáñez, Silvana Novelli, Miguel Teodoro Hernández-Garcia, María Manzanares, Reyes Arranz, José Javier Ferreiro, Sabella Bobillo, Santiago Mercadal, Andrea Galeo, Javier López Jiménez, José María Moraleda, Carlos Vallejo, Carmen Albo, Elena Pérez, Carmen Marrero, Laura Magnano, Luis Palomera, Isidro Jarque, Pilar Martínez-Sánchez, Alejandro Martín, Erika Coria, Armando López-Guillermo, Antonio Salar, Juan José Lahuerta
High-dose chemotherapy supported by autologous stem cell transplantation (HDT/ASCT) has contributed to modify the natural history of follicular lymphoma (FL); however, an overall survival (OS) benefit has been demonstrated at relapse only after a rituximab-free chemotherapy regimen. A total of 655 patients with FL were reported to the Spanish GELTAMO (Grupo Español de Linfomas y Trasplantes de Médula Ósea) registry and underwent first ASCT between 1989 and 2007. A total of 203 patients underwent ASCT in first complete response (CR1), 174 in second complete response (CR2), 28 in third complete response (CR3), 140 in first partial response (PR1), 81 in subsequent PR, and 29 with resistant/refractory disease; 184 patients received rituximab before ASCT...
May 19, 2017: Biology of Blood and Marrow Transplantation
https://www.readbyqxmd.com/read/28530668/radioimmunotherapy-augmented-beam-chemotherapy-vs-beam-alone-as-the-high-dose-regimen-for-autologous-stem-cell-transplantation-asct-in-relapsed-follicular-lymphoma-fl-a-retrospective-study-of-the-ebmt-lymphoma-working-party
#15
L Bento, A Boumendil, H Finel, S Le Gouill, S Amorim, H Monjanel, R Bouabdallah, J O Bay, E Nicolas-Virelizier, G McQuaker, G Rossi, R Johnson, A Huynh, P Ceballos, A Rambaldi, E Bachy, R Malladi, K Orchard, D Pohlreich, H Tilly, F Bonifazi, X Poiré, F Guilhot, A Haenel, C Crawley, B Metzner, J Gribben, N H Russell, G Damaj, K Thomson, P Dreger, S Montoto
Relapse remains the most common cause of treatment failure in patients receiving autologous stem cell transplantation (ASCT) for follicular lymphoma (FL). The aim of this study was to evaluate the effect of adding radioimmunotherapy or rituximab (R) to BEAM (carmustine, etoposide, ara-c, melphalan) high-dose therapy for ASCT in patients with relapsed FL. Using the European Society for Blood and Marrow Transplantation registry, we conducted a cohort comparison of BEAM (n=1973), Zevalin-BEAM (Z-BEAM) (n=207) and R-BEAM (n=179) and also a matched-cohort analysis of BEAM vs Z-BEAM including 282 and 154 patients, respectively...
May 22, 2017: Bone Marrow Transplantation
https://www.readbyqxmd.com/read/28509595/phase-ii-study-of-intensified-rituximab-induction-and-maintenance-for-low-grade-b-cell-lymphoma
#16
Hirokazu Nagai, Takeshi Shimomura, Makoto Takeuchi, Shuichi Hanada, Takuya Komeno, Kazutaka Sunami, Michihiro Hidaka, Takahiro Yano, Kiyoshi Kitano, Isao Yoshida, Nobumasa Inoue, Akiko Saito, Keizo Horibe, Suzuko Motitani, Shu Ichihara, Tomoyuki Watanabe, Morio Sawamura
Rituximab has markedly improved the outcomes of B cell lymphoma, and its maintenance has been shown to be beneficial in low grade B cell lymphoma (LGBCL). We conducted a multicenter, phase II trial of intensive rituximab induction and maintenance therapy for LGBCL to optimize the rituximab monotherapy. Patients with newly diagnosed or rituximab naïve relapsed LGBCL received 8 weekly rituximab as induction, then continued maintenance therapy with rituximab for 4 weeks at 6-month intervals. The primary endpoint was the overall response rate (ORR)...
May 16, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28487884/diffuse-large-b-cell-lymphoma-can-genomics-improve-treatment-options-for-a-curable-cancer
#17
REVIEW
Amit Dipak Amin, Tara L Peters, Lingxiao Li, Soumya Sundara Rajan, Ramesh Choudhari, Soham D Puvvada, Jonathan H Schatz
Gene-expression profiling and next-generation sequencing have defined diffuse large B-cell lymphoma (DLBCL), the most common lymphoma diagnosis, as a heterogeneous group of subentities. Despite ongoing explosions of data illuminating disparate pathogenic mechanisms, however, the five-drug chemoimmunotherapy combination R-CHOP remains the frontline standard treatment. This has not changed in 15 years, since the anti-CD20 monoclonal antibody rituximab was added to the CHOP backbone, which first entered use in the 1970s...
May 2017: Cold Spring Harbor Molecular Case Studies
https://www.readbyqxmd.com/read/28485023/a-randomized-phase-ii-study-of-standard-dose-versus-high-dose-rituximab-with-beam-in-autologous-stem-cell-transplantation-for-relapsed-aggressive-b-cell-non-hodgkin-lymphomas-long-term-results
#18
Samer A Srour, Shaoying Li, Uday R Popat, Muzaffar H Qazilbash, Sara Lozano-Cerrada, Farzeneh Maadani, Amin Alousi, Partow Kebriaei, Paolo Anderlini, Yago Nieto, Roy Jones, Elizabeth Shpall, Richard E Champlin, Chitra Hosing
High-dose rituximab (HD-R) combined with carmustine, cytarabine, etoposide and melphalan (BEAM) and autologous stem cell transplant (ASCT) was effective and tolerable in a single-arm prospective study of relapsed aggressive B-cell non-Hodgkin lymphoma (R-NHL). We performed a randomized phase 2 study comparing HD-R versus standard-dose rituximab (SD-R) in R-NHL. Ninety-three patients were randomized to HD-R (1000 mg/m(2) ) (n = 42) or SD-R (375 mg/m(2) ) (n = 51) administered on post-transplant days +1 and +8, using a Bayesian adaptive algorithm...
May 9, 2017: British Journal of Haematology
https://www.readbyqxmd.com/read/28482717/radiation-therapy-improves-survival-in-patients-with-testicular-diffuse-large-b-cell-lymphoma
#19
Jennifer C Ho, Bouthaina S Dabaja, Sarah A Milgrom, Grace L Smith, Jay P Reddy, Ali Mazloom, Ken H Young, Lijuan Deng, L Jeffrey Medeiros, Wenli Dong, Pamela K Allen, Therese Y Andraos, Nathan H Fowler, Loretta J Nastoupil, Yasuhiro Oki, Luis E Fayad, Francesco Turturro, Sattva S Neelapu, Jason Westin, Fredrick B Hagemeister, Maria Alma Rodriguez, Chelsea C Pinnix
In 120 Stage I-IV testicular diffuse large B-cell lymphoma (DLBCL) patients treated from 1964 to 2015, we assessed the benefits of prophylactic contralateral testicular radiation (RT) and prophylactic central nervous system (CNS) therapy on overall, progression free, testicular relapse free, and CNS relapse free survival (OS, PFS, TRFS, and CRFS, respectively). Seventy percent of patients received RT, 53% received anthracyclines and rituximab (modern therapy), and 61% received CNS prophylaxis. On univariate analysis RT was associated with improved TRFS, PFS, and trended toward improved OS...
May 9, 2017: Leukemia & Lymphoma
https://www.readbyqxmd.com/read/28475457/outcomes-of-patients-with-double-hit-lymphoma-who-achieve-first-complete-remission
#20
Daniel J Landsburg, Marissa K Falkiewicz, Joseph Maly, Kristie A Blum, Christina Howlett, Tatyana Feldman, Anthony R Mato, Brian T Hill, Shaoying Li, L Jeffrey Medeiros, Pallawi Torka, Francisco Hernandez-Ilizaliturri, Nishitha M Reddy, Arun Singavi, Timothy S Fenske, Julio C Chavez, Jason B Kaplan, Amir Behdad, Adam M Petrich, Martin A Bast, Julie M Vose, Adam J Olszewski, Cristiana Costa, Frederick Lansigan, James N Gerson, Stefan K Barta, Oscar Calzada, Jonathon B Cohen, Jennifer K Lue, Jennifer E Amengual, Xavier Rivera, Daniel O Persky, David J Peace, Sunita Nathan, Ryan D Cassaday
Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients with DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although the benefit of this treatment strategy is unclear. Methods Patients with DHL who achieved first complete remission following completion of front-line therapy with either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive front-line therapy, and deemed fit for autoSCT, were included...
May 5, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
keyword
keyword
114416
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"